![]() |
![]() |
Product | Quantum (Rs. Cr) | Long Term Rating | Short Term Rating |
Bank Loan Ratings | 68.24 | ACUITE BB+ | Reaffirmed & Withdrawn | - |
Bank Loan Ratings | 13.26 | Not Applicable | Withdrawn | - |
Total Outstanding | 0.00 | - | - |
Total Withdrawn | 81.50 | - | - |
Rating Rationale |
Acuite has reaffirmed and withdrawn the long-term rating of ‘ACUITE BB+' (read as ACUITE double B plus) on the Rs. 68.24 Cr. bank facilities of Nubeno Healthcare Private Limited (NHPL). The rating has been withdrawn on account of the request received from the company and the NOC (No Objection Certificate) received from the bankers. |
About the Company |
Incorporated in 2018, Maharashtra based Nubeno Healthcare Private Limited (NHPL) is engaged in manufacturing of medical equipment and surgical items such as intravenous (IV) cannula, syringes etc. Promoted by Nagpur based ‘Navbharat’ Group, the Company is owned and operated by Mr. Vaibhav Nimish Maheshwari and Mr. Raghav Nimish Maheshwari along with other family members. |
Unsupported Rating |
Not Applicable |
Analytical Approach |
Acuité has considered the standalone financial and business risk profiles of NHPL to arrive at the rating |
Key Rating Drivers |
Strengths |
Resourceful promoters, experienced management and diversified geographical presence, albeit limited track record of operations |
Weaknesses |
Intensive Working Capital Operations |
Rating Sensitivities |
Not Applicable |
Liquidity Position |
Adequate |
The liquidity profile of the company is adequate. The company generated a net cash accrual of Rs. 8.71 Cr. as on as on 31st March 2025(Provisional) against the debt repayment obligations of Rs. 7.83 Cr. in the same period. The current ratio of the company declined to 1.31 times as on 31st March 2025(Provisional) against 1.23 times as on 31st March 2024. The company also aims to generate sufficient net cash accruals which will help them to fulfil the debt repayment obligations in the future. Further, the average bank limit utilization at the month end balance stood low at 24% for 6 months ending February 2025. However, the average maximum limit utilized during the month stood at 76% for 6 month ended February 2025. Acuité believes that the liquidity of NHPL is likely to remain adequate over the medium term on account of steady cash accruals and no debt funded CAPEX plans in near future. |
Outlook: Not Applicable |
|
Other Factors affecting Rating |
None |
Particulars | Unit | FY 25 (Provisional) | FY 24 (Actual) |
Operating Income | Rs. Cr. | 96.21 | 64.24 |
PAT | Rs. Cr. | 3.87 | 3.02 |
PAT Margin | (%) | 4.02 | 4.71 |
Total Debt/Tangible Net Worth | Times | 1.69 | 1.80 |
PBDIT/Interest | Times | 2.75 | 4.26 |
Status of non-cooperation with previous CRA (if applicable) |
Not Applicable |
Interaction with Audit Committee anytime in the last 12 months (applicable for rated-listed / proposed to be listed debt securities being reviewed by Acuite) |
Not applicable |
Any other information |
None |
Applicable Criteria |
• Default Recognition :- https://www.acuite.in/view-rating-criteria-52.htm • Manufacturing Entities: https://www.acuite.in/view-rating-criteria-59.htm • Application Of Financial Ratios And Adjustments: https://www.acuite.in/view-rating-criteria-53.htm |
Note on complexity levels of the rated instrument |
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Contacts |
About Acuité Ratings & Research |
© Acuité Ratings & Research Limited. All Rights Reserved. | www.acuite.in |